MEI Pharma (MEIP) Rejects Unsolicited $8/sh Proposal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St gains on chip stocks recovery; earnings draw focus
- Oil prices rise over 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
MEI Pharma Board of Directors Rejects Unsolicited Proposal
June 1, 2023 8:00 AM EDTSAN DIEGO--(BUSINESS WIRE)-- MEI Pharma, Inc. (NASDAQ: MEIP) (the Company) today announced that its Board of Directors (the Board) reviewed and rejected the unsolicited and non-binding proposal received on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC to acquire all outstanding shares of MEI for not less than $8.00 in cash per share, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of the Companys clinical assets.
The Board, in consultation with the Companys financial and... More
